Lonza to sell therapeutic peptides business to PolyPeptide

By Gareth Macdonald contact

- Last updated on GMT

Lonza's peptides facility in Braine-l’Alleud, Belgium (source Google maps)
Lonza's peptides facility in Braine-l’Alleud, Belgium (source Google maps)

Related tags: Chromatography, Peptide synthesis, Protein

Lonza has agreed to sell its therapeutic peptide business to PolyPeptide Laboratories in a deal that will also see the latter firm take on 280 staff.

The deal – financial terms of which were not disclosed – will see Lonza’s peptide development and commercial-scale production facility in Braine-l’Alleud, Belgium change hands.

The takeover is expected to complete in the next few weeks.

A Lonza spokeswoman told us the facility produces therapeutic active pharmaceutical ingredients (APIs) using a variety of methods and technologies - liquid-phase peptide synthesis (LPPS), solid-phase peptide sythesis (SPPS), ligation and cyclization chemistry.

She also confirmed that all 280 Lonza employees at the facility will be joining Malmo, Sweden headquartered PolyPeptide Laboratories.

The Braine-l’Alleud site houses several HPLC (high-performance liquid chromatography) system thin film evaporators, freeze-dryers and a condenser. It also has a research and development lab and offices dedicated to logistics, procurement, HR, finance.

The Swiss firm described the unit as a niche business and said the divestiture will “streamline” its pharma and biotech segment.

Lonza stressed that operations at Braine-l’Alleud will not be impacted by the deal. 

Lonza paid former owner UCB €120m ($128m) for the site in 2006.

Polypeptide director Peter Nilsson told us "our aim is to get access to the large scale production capacity for customers in our current development portfolio and to continue to serve the existing customers of the facility.​"

Related news

Show more

Related products

show more

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more